Kidney News

Kidney News

Features

“I’m upset because no one has offered me a clinical trial. When I asked about a trial in clinic today, my nurse did not know what to say.”

Practice Pointers

The patient sitting in your office is in her low 30s, with an estimated GFR to match. She comes to you on referral from her primary care practice, unsure why she was referred, but the reason is pretty obvious to you.

Policy Update

ASN needs your help to ensure kidney transplant patients are able to access life-saving immunosuppressive medications.

Findings

Some groups of patients with clinically localized kidney tumors and severe chronic kidney disease (CKD) are at high risk of adverse outcomes after partial nephrectomy (PN), according to a study in The Journal of Urology.

April 2017 Issue

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic medications that have been demonstrated to improve cardiovascular outcomes in patients with diabetes. SGLT2 inhibitors regulate serum glucose levels by selectively blocking type 2 glucose transporters in the proximal convoluted tubules, thereby reducing the amount of glucose and sodium reabsorbed.

All Issues

Read past issues of
ASN Kidney News.

Established in 2009, ASN Kidney News has kept the kidney community informed of the latest clinical, scientific, and policy issues affecting kidney health professionals and patients with kidney disease.

Video Library

ASN Executive Director Tod Ibrahim discusses a variety of nephrology related topics.

ASN Executive Director Tod Ibrahim discusses a variety of nephrology related topics.

ASN Executive Director Tod Ibrahim discusses a variety of nephrology related topics. The American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.